Dosing Begins in Phase 2 Trial of XPro1595, Targeting Inflammation

A first patient has been dosed in a Phase 2 trial of XPro1595, INmune Bio’s candidate therapy for Alzheimer’s disease. The MINDFuL trial (NCT05318976) aims to recruit around 201 people, ages 60–85, with mild Alzheimer’s and biomarkers of brain inflammation across multiple sites in the U.S., Australia, and Canada. Top-line results are expected in 2023. For more information on enrollment, including trial sites, those interested can contact INmune at trials@inmunebio.com. Recommended Reading April 14, 2022 News…

You must be logged in to read/download the full post.